Barr Labs Among Generic-Drug Makers Focusing on Biotech Market
This article is for subscribers only.
Barr Laboratories Inc. is among a group of generic-drug makers pressing lawmakers for an easier approval process to copy biotechnology medicines, a market that generates more than $21 billion in global sales.
The companies want to speed approvals in much the same way a 1984 law did for traditional prescription medicines. After that measure was passed, generic-drug companies more than doubled their share of prescriptions. Two decades ago, Congress left out of legislation the then-nascent biotech industry, which makes therapies from proteins and living organisms.